# SageMedic Corp.

> SageMedic Corp. is a Redwood City, California biotech and CLIA-accredited laboratory advancing functional precision oncology. Its flagship product, the SAGE Oncotest, grows hundreds of live 3D microtumors from a patient's own fresh tumor biopsy and tests them against a panel of FDA-approved chemotherapies and targeted drugs, predicting which treatments a tumor will resist or respond to within 7-10 days - independently of genetic mutations. The company reports actionable results in 88% of cases versus roughly 26% for genomic tests. Founded by physician-scientists Dr. Chris Apfel and Dr. Brigitte Apfel, SageMedic aims to more than double a patient's odds of receiving the most effective therapy the first time.

- **Founded:** 2018
- **Headquarters:** Redwood City, California, United States
- **Founders:** Dr. Chris Apfel (Founder, CEO & Chairman), Dr. Brigitte Apfel (Co-Founder & Treasurer)
- **Team size:** ~11 employees
- **Products:** SAGE Oncotest, SAGE Direct Platform
- **Notable:** Reports actionable results in 88% of cases versus ~26% for genomic tests, Delivers drug-response results within 7-10 days from a fresh biopsy, CLIA-certified (ID 05D2236809), COLA-accredited, CMS-certified laboratory

## Products & services

- **SAGE Oncotest** — A proprietary, patent-protected ex-vivo, high-throughput 3D assay that grows hundreds of live microtumors from a patient's fresh tumor biopsy and tests them against a panel of FDA-approved chemotherapies and targeted therapies, predicting tumor resistance and response independently of genetic mutations, with results in 7-10 days.
- **SAGE Direct Platform** — A genome-free precision medicine platform that directly tests candidate cancer treatments on live patient tissue biopsies to identify effective therapies.

## Achievements

- Reports actionable results in 88% of cases versus ~26% for genomic tests
- Delivers drug-response results within 7-10 days from a fresh biopsy
- CLIA-certified (ID 05D2236809), COLA-accredited, CMS-certified laboratory
- Presented ovarian cancer tumor-heterogeneity research at AACR 2025
- Founder Dr. Chris Apfel developed the globally used Apfel Score for postoperative nausea risk

## Latest updates

- **2025-04** — SageMedic showcased treatment-matching via functional precision oncology at the AACR Annual Meeting 2025 in Chicago, including a poster on heterogeneity of ex-vivo tumor responses in primary ovarian cancer tissues.

## Links

- Website: https://sagemedic.com
- LinkedIn: https://www.linkedin.com/company/sagemedic
- Facebook: https://www.facebook.com/SageMedic/

---

Profile page: https://yespress.io/sagemedic-corp
Published by YesPress — https://yespress.io
Last updated: 2026-07-10